Literature DB >> 12070008

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.

Elaine Coustan-Smith1, Jose Sancho, Frederick G Behm, Michael L Hancock, Bassem I Razzouk, Raul C Ribeiro, Gaston K Rivera, Jeffrey E Rubnitz, John T Sandlund, Ching-Hon Pui, Dario Campana.   

Abstract

Early clearance of leukemic cells is a favorable prognostic indicator in childhood acute lymphoblastic leukemia (ALL). However, identification of residual leukemic cells by their morphologic features is subjective and lacks sensitivity. To improve estimates of leukemia clearance, we applied flow cytometric techniques capable of detecting 1 leukemic cell in 10,000 or more normal cells and prospectively measured residual leukemia in bone marrow samples collected on day 19 of remission-induction chemotherapy from 248 children with newly diagnosed ALL. In 134 samples (54.0%), we identified at least 0.01% leukemic cells (0.01%-< 0.1% in 51 samples [20.6%], 0.1%-< 1% in 36 [14.5%], and > or = 1% in 47 [19.0%]). Among 110 children treated within a single chemotherapy program, the 5-year mean +/- SE cumulative incidence of relapse or failure to achieve remission was 32.2% +/- 6.5% for the 59 patients with 0.01% residual leukemic cells or greater on day 19 and 6.0% +/- 3.4% for the 51 patients with less than 0.01% leukemic cells (P <.001). The prognostic value of day-19 bone marrow status defined by flow cytometry was superior to that defined by morphologic studies and remained significant after adjustment for other clinical and biologic variables. Lack of detectable leukemic cells on day 19 was more closely associated with relapse-free survival than was lack of detectable residual disease at the end of remission induction (day 46). Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070008     DOI: 10.1182/blood-2002-01-0006

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.

Authors:  J Moppett; G A A Burke; C G Steward; A Oakhill; N J Goulden
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

2.  Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Authors:  Christian Flotho; Elaine Coustan-Smith; Deqing Pei; Shotaro Iwamoto; Guangchun Song; Cheng Cheng; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

3.  Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.

Authors:  Giuseppe Gaipa; Giovanni Cazzaniga; Maria Grazia Valsecchi; Renate Panzer-Grümayer; Barbara Buldini; Daniela Silvestri; Leonid Karawajew; Oscar Maglia; Richard Ratei; Alessandra Benetello; Simona Sala; Angela Schumich; Andre Schrauder; Tiziana Villa; Marinella Veltroni; Wolf-Dieter Ludwig; Valentino Conter; Martin Schrappe; Andrea Biondi; Michael N Dworzak; Giuseppe Basso
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

4.  New markers for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Christopher Clark; Laura Key; Peixin Liu; Mohammad Mehrpooya; Patricia Stow; Xiaoping Su; Sheila Shurtleff; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

Review 5.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

6.  Evaluating New Markers for Minimal Residual Disease Analysis by Flow Cytometry in Precursor B Lymphoblastic Leukemia.

Authors:  Sonal Jain; Anurag Mehta; Gauri Kapoor; Dinesh Bhurani; Sandeep Jain; Narendra Agrawal; Rayaz Ahmed; Dushyant Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2017-07-03       Impact factor: 0.900

7.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

8.  A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.

Authors:  Elaine Coustan-Smith; Raul C Ribeiro; Patricia Stow; Yinmei Zhou; Ching-Hon Pui; Gaston K Rivera; Francisco Pedrosa; Dario Campana
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

9.  Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.

Authors:  Faith Galderisi; Linda Stork; Ju Li; Motomi Mori; Solange Mongoue-Tchokote; James Huang
Journal:  Pediatr Blood Cancer       Date:  2009-10       Impact factor: 3.167

10.  Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Authors:  C H Pui; D Pei; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Raimondi; M Onciu; D Campana; L E Kun; S Jeha; C Cheng; S C Howard; M L Metzger; D Bhojwani; J R Downing; W E Evans; M V Relling
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.